The pharmaceutical community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s exhibiting significant promise in clinical trials for addressing obesity. Unlike some current weight loss approaches, retatrutide appears to provide a greater substantial lo